Page 6 - மெய்நிகர் அறிவியல் ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article HORSHAM, Pa., May 21, 2021 /PRNewswire/  The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANT TM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. 1 RYBREVANT TM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.

United statesJill feldmanChristopher deloreficeJoshuak sabariPeter lebowitzJanssen carepathRybrevant janssencarepathsavingsJennifer mcintyreAnia diantonioMathai mammenNational cancer instituteJanssen biotech incJanssen pharmaceutical companies of johnsonJanssen research developmentJanssen carepath savings programYork university langone perlmutter cancer center